| Control subjects | |||||
| Patients | Patients with asthma | Healthy subjects | |||
| DYAR n = 23 | IAR n = 24 | LAR n = 16 | DAR n = 17 | n = 25 | |
| Age (years) | 27 ± 8 | 30 ± 4 | 29 ± 6 | 28 ± 4 | 30 ± 7 |
| Gender (M/F) | 11/12 | 10/14 | 7/9 | 9/8 | 12/13 |
| Disease history (years) | 4.8 ± 2.2 | 4.5 ± 2.7 | 5.1 ± 2.1 | 4.8 ± 2.9 | 0 |
| Asthmatic attacks per month | 3 ± 1 | 4 ± 1 | 3 ± 2 | 3 ± 2 | 0 |
| FEV 1 (% predicted) | 95.2 ± 6.1 | 97.5 ± 6.3 | 97.2 ± 3.5 | 99.2 ± 3.1 | 104.3 ± 2.5 |
| FVC (% predicted) | 98.7 ± 4.1 | 98.3 ± 3.3 | 99.3 ± 2.0 | 98.2 ± 4.4 | 103.4 ± 5.3 |
| Blood leukocyte count (× 109/L)○ | 10.1 ± 0.9+ | 6.3 ± 1.1 | 8.0 ± 1.7 | 8.2 ± 0.7 | 7.1 ± 0.5 |
| Blood eosinophil count (× 106/L)○○ | 373 ± 45 | 569 ± 71* | 544 ± 35* | 551 ± 53* | 265 ± 24 |
| Blood thrombocyte count (× 109/L)○○○ | 324 ± 58 | 311 ± 24 | 346 ± 35 | 279 ± 39 | 306 ± 28 |
| Bronchial histamine threshold□ | |||||
| ≤2.0 mg/mL | 2 | 3 | 2 | 3 | 0 |
| 4.0 mg/mL | 1 | 4 | 1 | 2 | 0 |
| 8.0 mg/mL | 2 | 6 | 5 | 3 | 0 |
| 16.0 mg/mL | 7 | 3 | 3 | 4 | 0 |
| 32.0 mg/mL | 5 | 5 | 3 | 3 | 1 |
| >32.0 mg/mL | 6 | 3 | 2 | 2 | 24 |
| Positive skin response (i.c.) | |||||
| Immediate | 8 | 21 | 5 | 10 | 0 |
| Late | 2 | 3 | 11 | 7 | 0 |
| Delayed | 13 | 0 | 0 | 0 | 0 |
| Increased total IgE in serum■ | 0 | 6 | 3 | 7 | 0 |
| Positive specific IgE in serum■■ | 0 | 15 | 10 | 11 | 0 |
| Increased total IgG in serum■■■ | 0 | 0 | 9 | 8 | 0 |
| Increased IgG sub-classes in serum∆ | |||||
| IgG1 | 0 | 0 | 2 | 1 | 0 |
| IgG2 | 0 | 0 | 0 | 1 | 0 |
| IgG3 | 0 | 0 | 3 | 2 | 0 |
| IgG4 | 0 | 0 | 5 | 2 | 0 |
| Increased total IgM in serum∆∆ | 0 | 0 | 0 | 0 | 0 |
| Increased total IgA in serum∆∆∆ | 0 | 0 | 0 | 0 | 0 |
| Ratio Th1 /Th2 (%) in blood▲ | 8.5 ± 2.1+ | 6.4 ± 2.2 | 6.6 ± 2.0 | 6.8 ± 2.4 | 7.0 ± 2.3 |
| IFN-γ (pg/mL)-PBMC▲▲ | 377 ± 45+ | 219 ± 30 | 236 ± 42 | 198 ± 51 | 232 ± 46 |
| IL-4 (pg/mL)-PBMC▲▲ | 17.1 ± 6.3 | 23.5 ± 4.0+ | 21.6 ± 4.0 | 24.4 ± 2.5+ | 16.8 ± 3.0 |